Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9109652 | 1.00 | MAOB (0.44) | MAOBLMNAMAOASLC6A2PKM | |
| SCHEMBL9243943 | 1.00 | MAOB (0.44) | MAOBLMNAMAOASLC6A2PKM | |
| SCHEMBL2896669 | 0.81 | DDB1 (0.40) | MAOBSLC6A2 | |
| SCHEMBL8234131 | 0.81 | USP2 (0.35) | LMNAMAOASLC6A2PKMMAPT | |
| SCHEMBL20840267 | 0.81 | DDB1 (0.40) | MAOBSLC6A2 | |
| SCHEMBL5021254 | 0.81 | MAOB (0.44) | MAOB | |
| SCHEMBL2901706 | 0.81 | SLC6A3 (0.46) | SLC6A2 | |
| SCHEMBL2722147 | 0.81 | SLC6A3 (0.46) | SLC6A2 | |
| SCHEMBL2893585 | 0.81 | MAOB (0.44) | MAOB | |
| SCHEMBL2899162 | 0.81 | HSD17B10 (0.47) | MAOBLMNAMAOAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007078523-A2 | 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014357-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | MAOB 1062/4885LMNA 449/4885MAOA 1991/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | MAOB 1062/4885LMNA 449/4885MAOA 1991/4885 |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | MAOB 1953/4885LMNA 4716/4885MAOA 2435/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | MAOB 1062/4885LMNA 449/4885MAOA 1991/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | MAOB 1062/4885LMNA 449/4885MAOA 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.